The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.

J Acquir Immune Defic Syndr · 2019 · PMC6467556 · PMID 30789452

Europe PMC DOI

hedged sentence

0.3500

closest p · 7.0× alpha

0.3500

boldest claim

The sentences

showed a trendP = 0.35not close (p > 0.1)

FIB-4 also showed a trend toward a more prominent reduction in the MVC + DRV/r arm (−0.02; IQR −0.21 to +0.13) vs 3-drug ART arm (+0.02; IQR −0.23 to +0.20) ( P = 0.35) at week 48 (Fig. 1 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.